KalVista Pharmaceuticals (NASDAQ:KALV) Earns Outperform Rating from Analysts at JMP Securities

JMP Securities started coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research note released on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $19.00 price target on the specialty pharmaceutical company’s stock.

Several other analysts have also weighed in on the company. TD Cowen began coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Stock Up 1.6 %

KALV stock opened at $8.91 on Friday. The company has a fifty day simple moving average of $8.83 and a two-hundred day simple moving average of $10.84. KalVista Pharmaceuticals has a 52 week low of $7.30 and a 52 week high of $16.88. The firm has a market capitalization of $440.31 million, a P/E ratio of -2.45 and a beta of 0.86.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, analysts anticipate that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,627 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the transaction, the chief executive officer now owns 274,596 shares in the company, valued at approximately $2,677,311. The trade was a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,291 shares of company stock worth $304,086 in the last 90 days. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company increased its holdings in KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 3,314 shares during the period. SG Americas Securities LLC purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at $153,000. China Universal Asset Management Co. Ltd. raised its position in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 3,328 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its stake in shares of KalVista Pharmaceuticals by 23.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after purchasing an additional 121,615 shares during the last quarter. Finally, Emerald Advisers LLC boosted its position in KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after purchasing an additional 192,091 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).